アイスランド - アイスランド語 - LYFJASTOFNUN (Icelandic Medicines Agency)

pfizer aps - cytarabinum inn - stungulyf/innrennslislyf, lausn - 100 mg/ml

アイスランド - アイスランド語 - LYFJASTOFNUN (Icelandic Medicines Agency)

accord healthcare b.v. - etoposidum inn - innrennslisþykkni, lausn - 20 mg/ml

アイスランド - アイスランド語 - LYFJASTOFNUN (Icelandic Medicines Agency)

evolan pharma ab - melatoninum inn; sucralose - mixtúra, lausn - 1 mg/ml

アイスランド - アイスランド語 - LYFJASTOFNUN (Icelandic Medicines Agency)

heilsa ehf. - diclofenacum inn tvíetýlamín - hlaup - 23,2 mg/g

アイスランド - アイスランド語 - LYFJASTOFNUN (Icelandic Medicines Agency)

colgate palmolive a/s - natrii fluoridum - tanndreifa - 22,6 mg/ml

欧州連合 - アイスランド語 - EMA (European Medicines Agency)

pfizer europe ma eeig - tafamidis - amyloidosis - Önnur lyf í taugakerfinu - vyndaqel er ætlað fyrir meðferð transthyretin amyloidosis í fullorðinn sjúklinga með stigi-1 einkennum polyneuropathy að tefja útlæga taugasköddun skert.

欧州連合 - アイスランド語 - EMA (European Medicines Agency)

aop orphan pharmaceuticals gmbh - ropeginterferon alfa-2b - blóðríki - Ónæmisörvandi, - besremi er ætlað eitt og sér í fullorðnir fyrir meðferð polycythaemia vera án einkenna miltisstækkun.

欧州連合 - アイスランド語 - EMA (European Medicines Agency)

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - Æxlishemjandi lyf - dasatinib accord is indicated for the treatment of adult patients with:• ph+ acute lymphoblastic leukaemia (all) with resistance or intolerance to prior therapy. dasatinib accord is indicated for the treatment of paediatric patients with:• newly diagnosed ph+ all in combination with chemotherapy.

アイスランド - アイスランド語 - LYFJASTOFNUN (Icelandic Medicines Agency)

ratiopharm gmbh* - amoxicillinum tríhýdrat - mixtúruduft, dreifa - 100 mg/ml

アイスランド - アイスランド語 - LYFJASTOFNUN (Icelandic Medicines Agency)

essential pharma limited - haloperidolum dekanóat - stungulyf, lausn - 100 mg/ml